UNIBIO A/S - CVR: 26110262

2022, DKK

14.04.2023

Bruttoresultat

-12.558'

Primær drift

-58.489'

Årets resultat

-49.325'

Aktiver

71.344'

Kortfristede aktiver

46.011'

Egenkapital

33.531'

Afkastningsgrad

-82 %

Soliditetsgrad

47 %

Likviditetsgrad

122 %

Resultat

14.04.2023

Årsrapport	2022 14.04.2023	2021 10.06.2022	2020 03.06.2021	2019 22.05.2020	2018 03.06.2019	2017 12.03.2018	2016 16.02.2017	2015 03.06.2016
Nettoomsætning
Bruttoresultat	-12.558.000	-13.393.000	-13.099.000	-10.422.000	-7.449.000	-2.313.000	1.141.000	-2.688.000
Resultat af primær drift	-58.489.000	-48.391.000	-44.732.000	-32.668.000	-24.951.000	-16.233.000	-7.112.000	-6.174.000
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	3.884.000	2.276.000	81.000	128.000	6.000	0	3.000	2.000
Finansieringsomkostninger	0	0	0	0	0	0	0	0
Andre finansielle omkostninger	-220.000	-1.418.000	-2.501.000	-777.000	-625.000	-309.000	0	-2.000
Resultat før skat	-54.825.000	-47.533.000	-47.152.000	-33.317.000	-25.570.000	-16.542.000	-7.109.000	-6.174.000
Resultat	-49.325.000	-41.849.000	-41.743.000	-25.985.000	-19.953.000	-12.906.000	-4.554.000	-4.631.000
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

14.04.2023

Årsrapport	2022 14.04.2023	2021 10.06.2022	2020 03.06.2021	2019 22.05.2020	2018 03.06.2019	2017 12.03.2018	2016 16.02.2017	2015 03.06.2016
Kortfristede varebeholdninger	630.000	512.000	315.000	396.000	433.000	381.000	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	19.185.000	19.487.000	24.469.000	15.114.000	14.148.000	8.064.000	8.947.000	5.023.000
Likvider	26.196.000	72.527.000	15.830.000	64.940.000	4.016.000	1.957.000	1.580.000	293.000
Kortfristede aktiver	46.011.000	92.526.000	40.614.000	80.450.000	18.597.000	10.402.000	10.527.000	5.316.000
Immaterielle aktiver og goodwill	1.372.000	1.572.000	1.991.000	4.095.000	4.261.000	5.187.000	5.742.000	6.278.000
Finansielle anlægsaktiver	525.000	300.000	150.000	150.000	100.000	100.000	100.000	0
Materielle aktiver	23.436.000	24.478.000	24.913.000	20.840.000	21.474.000	18.631.000	12.676.000	0
Langfristede aktiver	25.333.000	26.350.000	27.054.000	25.085.000	25.835.000	23.918.000	18.518.000	6.278.000
Aktiver	71.344.000	118.876.000	67.668.000	105.535.000	44.432.000	34.320.000	29.045.000	11.594.000

Aktiver

14.04.2023

Passiver

14.04.2023

Årsrapport	2022 14.04.2023	2021 10.06.2022	2020 03.06.2021	2019 22.05.2020	2018 03.06.2019	2017 12.03.2018	2016 16.02.2017	2015 03.06.2016
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	33.531.000	-17.144.000	24.705.000	66.447.000	15.801.000	15.755.000	14.661.000	7.213.000
Hensatte forpligtelser	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	3.054.000	4.086.000	2.038.000	1.546.000	1.943.000	3.571.000	2.337.000	1.715.000
Kortfristede forpligtelser	37.813.000	136.020.000	35.378.000	32.058.000	21.768.000	11.725.000	14.384.000	4.381.000
Gældsforpligtelser	37.813.000	136.020.000	42.963.000	39.088.000	28.631.000	18.565.000	14.384.000	4.381.000
Forpligtelser	37.813.000	136.020.000	42.963.000	39.088.000	28.631.000	18.565.000	14.384.000	4.381.000
Passiver	71.344.000	118.876.000	67.668.000	105.535.000	44.432.000	34.320.000	29.045.000	11.594.000

Passiver

14.04.2023

Nøgletal

14.04.2023

Årsrapport	2022 14.04.2023	2021 10.06.2022	2020 03.06.2021	2019 22.05.2020	2018 03.06.2019	2017 12.03.2018	2016 16.02.2017	2015 03.06.2016
Afkastningsgrad	-82,0 %	-40,7 %	-66,1 %	-31,0 %	-56,2 %	-47,3 %	-24,5 %	-53,3 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-147,1 %	244,1 %	-169,0 %	-39,1 %	-126,3 %	-81,9 %	-31,1 %	-64,2 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Soliditestgrad	47,0 %	-14,4 %	36,5 %	63,0 %	35,6 %	45,9 %	50,5 %	62,2 %
Likviditetsgrad	121,7 %	68,0 %	114,8 %	251,0 %	85,4 %	88,7 %	73,2 %	121,3 %

Resultat

14.04.2023

Gæld

14.04.2023

Årsrapport

14.04.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 14.04.2023)

Information om virksomhedens regnskabsklasse:This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of a few provisions for reporting class C. The accounting policies applied to these financial statements are consistent with those applied last year.

Beretning

14.04.2023

Dato for ledelsens godkendelse af årsrapporten:2023-03-31

Beskrivelse af usikkerhed ved indregning eller måling:Uncertainty relating to recognition and measurementThe company's going concern are secured through letter of support from the parent company. The letter of support ensures that the company can meet its obligations as they fall due, just as the statement of support ensures that the parent company will not claim to be repaid until there is liquidity for this. The letter of support secures the company's further development and operation. In Management’s view, there is no other specific uncertainty about the recognition or measurement of any items in the financial statements .

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Board of Directors and the Executive Board have today considered and approved the annual report of Unibio A/S for the financial year 01. 01. 2022 - 31. 12. 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesUnibio – protein production for the future Unibio is a fast-growing, innovative, sustainable protein company with the U-Loop® technology to produce single-cell protein in unlimited amounts. With a rapidly growing global population and drecreasing food security, there is a huge demand for sustainable products like Unibio’s single-cell protein, Uniprotein®, to avoid depleting the world’s natural resources. Unibio has developed this technology to industrial scale and is rolling it out globally. Unibio’s technology enables customers access to high quality protein and improves food security worldwide. Figure 1; Expected demographic development from 2010 to 2050. Source: World Resources Institute Unibio’s technology has been proven at industrial scale and is commercialized. Unibio continues to enhance the technology to increase performance and lower production costs. Unibio is in dialogue with potential partners around the world who are interested in licensing or forming Joint Ventures with Unibio to help accelerate the deployment of the technology. There is significant interest in Uniprotein® and the Company is actively engaged with customers in the feed/aquaculture area as well as pet food.